Rani Therapeutics Enters Material Definitive Agreement
Ticker: RANI · Form: 8-K · Filed: Jun 24, 2024 · CIK: 1856725
| Field | Detail |
|---|---|
| Company | Rani Therapeutics Holdings, Inc. (RANI) |
| Form Type | 8-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement
TL;DR
Rani Therapeutics signed a big deal on 6/17, details TBD.
AI Summary
Rani Therapeutics Holdings, Inc. announced on June 17, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details of the agreement, the counterparty, or any associated financial figures.
Why It Matters
This filing indicates a significant new development for Rani Therapeutics, potentially impacting its business operations and future strategies.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the material definitive agreement.
Key Players & Entities
- Rani Therapeutics Holdings, Inc. (company) — Registrant
- June 17, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Rani Therapeutics?
The filing does not specify the nature of the material definitive agreement.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the identity of the other party to the agreement.
What is the effective date of this material definitive agreement?
The earliest event reported is June 17, 2024.
Are there any financial terms or obligations associated with this agreement disclosed in the filing?
No financial terms or obligations are disclosed in this filing.
Does this agreement represent a significant change in Rani Therapeutics' business operations?
The filing states it is a 'material definitive agreement,' implying it is significant, but the specific impact is not detailed.
Filing Stats: 1,046 words · 4 min read · ~3 pages · Grade level 14.8 · Accepted 2024-06-24 07:16:34
Key Financial Figures
- $0.0001 — stered Class A common stock, par value $0.0001 per share RANI The Nasdaq Stock Mar
Filing Documents
- d841207d8k.htm (8-K) — 31KB
- d841207dex991.htm (EX-99.1) — 40KB
- g841207ex99_1s10g1.jpg (GRAPHIC) — 34KB
- g841207ex99_1s11g1.jpg (GRAPHIC) — 95KB
- g841207ex99_1s12g1.jpg (GRAPHIC) — 125KB
- g841207ex99_1s13g1.jpg (GRAPHIC) — 75KB
- g841207ex99_1s14g1.jpg (GRAPHIC) — 40KB
- g841207ex99_1s15g1.jpg (GRAPHIC) — 100KB
- g841207ex99_1s16g1.jpg (GRAPHIC) — 105KB
- g841207ex99_1s17g1.jpg (GRAPHIC) — 99KB
- g841207ex99_1s18g1.jpg (GRAPHIC) — 144KB
- g841207ex99_1s19g1.jpg (GRAPHIC) — 35KB
- g841207ex99_1s1g1.jpg (GRAPHIC) — 50KB
- g841207ex99_1s20g1.jpg (GRAPHIC) — 82KB
- g841207ex99_1s21g1.jpg (GRAPHIC) — 58KB
- g841207ex99_1s22g1.jpg (GRAPHIC) — 105KB
- g841207ex99_1s23g1.jpg (GRAPHIC) — 101KB
- g841207ex99_1s24g1.jpg (GRAPHIC) — 43KB
- g841207ex99_1s25g1.jpg (GRAPHIC) — 105KB
- g841207ex99_1s26g1.jpg (GRAPHIC) — 79KB
- g841207ex99_1s27g1.jpg (GRAPHIC) — 90KB
- g841207ex99_1s28g1.jpg (GRAPHIC) — 82KB
- g841207ex99_1s29g1.jpg (GRAPHIC) — 87KB
- g841207ex99_1s2g1.jpg (GRAPHIC) — 155KB
- g841207ex99_1s30g1.jpg (GRAPHIC) — 75KB
- g841207ex99_1s31g1.jpg (GRAPHIC) — 102KB
- g841207ex99_1s32g1.jpg (GRAPHIC) — 87KB
- g841207ex99_1s33g1.jpg (GRAPHIC) — 31KB
- g841207ex99_1s34g1.jpg (GRAPHIC) — 178KB
- g841207ex99_1s3g1.jpg (GRAPHIC) — 88KB
- g841207ex99_1s4g1.jpg (GRAPHIC) — 44KB
- g841207ex99_1s5g1.jpg (GRAPHIC) — 71KB
- g841207ex99_1s6g1.jpg (GRAPHIC) — 77KB
- g841207ex99_1s7g1.jpg (GRAPHIC) — 116KB
- g841207ex99_1s8g1.jpg (GRAPHIC) — 115KB
- g841207ex99_1s9g1.jpg (GRAPHIC) — 82KB
- 0001193125-24-166293.txt ( ) — 4282KB
- rani-20240617.xsd (EX-101.SCH) — 3KB
- rani-20240617_lab.xml (EX-101.LAB) — 18KB
- rani-20240617_pre.xml (EX-101.PRE) — 11KB
- d841207d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Presentation dated June 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 24, 2024 Rani Therapeutics Holdings, Inc. By: /s/ Svai Sanford Svai Sanford Chief Financial Officer